Secondary Resistance to Anti-EGFR Therapy by Transcriptional Reprogramming in Patient-Derived Colorectal Cancer Models
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141861
下载链接
链接失效反馈官方服务：
资源简介：
3' RNA-seq of patient derived colon cancer xenograft models (N=10) showing initial disease control under cetuximab treatment were collected. All xenograft models were wildtype for KRAS, NRAS, BRAF and PIK3CA. All mice were treated with cetuximab (Merck Serono) by intra peritoneal (i.p.) injection twice per week and dosed at 25mg/kg to establish response characteristics. Tumors were chronically treated to establish cetuximab secondary resistant tumors . Three conditions were generated for comparisons: untreated control (K), 5 days cetuximab treatment (5dC) while pdx tumors were responsive to cetuximab and cetuximab secondary resistant tumors (C) following chronic cetuximab treatment.
创建时间：
2021-07-27
